Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference, taking place January 10 - 13, 2022.
40th Annual J.P. Morgan Healthcare Conference
|Date:||Thursday, January 13th, 2022|
|Time:||9:45am Eastern Time|
|Webcast:||The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com|
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (batoclimab), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Released January 7, 2022